Buying guide
Lingo vs Oura Ring 4 in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Abbott | Oura |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $349-$499 or $70/year lease or $6/month subscription (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Abbott | 1Oura |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 12cloud-upload, biometric-storage, data-sale, data-deletion-control, biometric-storage, data-retention, location-tracking, training-data-use, biometric-storage, data-sale, data-deletion-control, data-retention |
| Sources on file | 8 | 23 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Oura Ring 4
The Oura Ring 4 (Gen 4, late 2024, from Oura, founded 2013 in Oulu, Finland) is a titanium biometric smart ring and the study-first archetype of the biometric cohort. Its 'Smart Sensing' recessed sensors (PPG heart rate and HRV, red and infrared blood-oxygen, multi-point skin temperature, accelerometer) feed 50-plus metrics: sleep staging and Sleep Score, Readiness, Activity, stress, cycle tracking, a VO2 Max estimate, and an LLM 'Oura Advisor'. It is sold as a purchase (from about $349) plus a required Oura Membership ($5.99/month); the AI augments genuine biometric sensing rather than being the product. DEPLOY records commercial maturity and a reported $11 billion valuation (October 2025). The verified-vs-claimed throughline: Oura is positioned as general wellness and is not FDA-cleared for diagnostics, and it ran a blood-pressure study in December 2025 before marketing blood pressure, the study-first counterpoint to Whoop's market-first BP Insights. Oura is also the patent-holder in the smart-ring litigation (RingConn settled; Ultrahuman was ITC import-banned via the '178 patent).
Machine-readable: this page as markdown.